Tenosynovial giant cell tumour (TGCT): lines of therapy
3 standard-of-care settings across 2 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
Early / localised
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Localised TGCT | Marginal excision; recurrence is uncommon and re-excision is curative in most cases. | NCCN Soft Tissue Sarcoma; TGCT consensus (Stacchiotti, Cancer Treat Rev 2023) | 40 | |
| All comers | Diffuse TGCT, resectable | Open or arthroscopic synovectomy by a sarcoma orthopaedic team; consider neoadjuvant CSF1R inhibition for large tumours (trial setting). | 40 |
Second line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Diffuse TGCT where surgery would cause severe morbidity or after recurrence | CSF1R inhibitor: vimseltinib (MOTION) or pexidartinib (ENLIVEN, with REMS hepatic monitoring); imatinib or nilotinib off label where neither is available. | NCCN · Category 2A | 78 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.